论文部分内容阅读
目的探讨不同剂量替米沙坦联合前列地尔治疗早期糖尿病肾病的疗效。方法将82例糖尿病肾病患者随机分为3组,第一、二组给予正常剂量替米沙坦80 mg治疗,第三组给予大剂量替米沙坦160 mg治疗;第二、三组同时联合前列地尔10μg/d静脉注射;各组均接受糖尿病饮食、降糖、调脂治疗,总疗程4周。观察治疗前后3组患者的24 h尿白蛋白定量、血肌酐、血尿素氮、血钾和平均动脉压。结果替米沙坦联合前列地尔对早期糖尿病肾病有明显的降低蛋白尿作用,大剂量替米沙坦组的治疗效果更明显(P<0.01)。结论替米沙坦联合前列地尔能够有效治疗早期糖尿病肾病,且大剂量组的效果更明显。
Objective To investigate the effect of different doses of telmisartan and alprostadil in the treatment of early diabetic nephropathy. Methods 82 patients with diabetic nephropathy were randomly divided into three groups, the first and second groups were given normal dose telmisartan 80 mg treatment, the third group was given high-dose telmisartan 160 mg treatment; the second and third groups simultaneously combined Alprostadil 10μg / d intravenous injection; each group received diabetic diet, hypoglycemic, lipid-lowering treatment, the total course of 4 weeks. The levels of 24 h urinary albumin, serum creatinine, blood urea nitrogen, serum potassium and mean arterial pressure were observed in 3 groups before and after treatment. Results Telmisartan combined with alprostadil had a significant effect of reducing proteinuria on early diabetic nephropathy. The treatment with high-dose telmisartan was more effective (P <0.01). Conclusion Telmisartan combined with alprostadil can effectively treat early diabetic nephropathy, and the effect of high-dose group is more obvious.